However, It is also worth mentioning that HDAC inhibitors are currently being studied in ALS associated with FUS or TARDBP-43 mutations, so it is not clear whether this therapy would also be effective in sporadic ALS cases. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.